{"id":393448,"date":"2025-11-21T00:45:41","date_gmt":"2025-11-21T00:45:41","guid":{"rendered":"https:\/\/www.europesays.com\/us\/393448\/"},"modified":"2025-11-21T00:45:41","modified_gmt":"2025-11-21T00:45:41","slug":"onconano-taps-veteran-biopharmaceutical-leader-as-its-new-chief-operating-officer-dallas-innovates","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/393448\/","title":{"rendered":"OncoNano Taps Veteran Biopharmaceutical Leader as Its New Chief Operating Officer \u00bb Dallas Innovates"},"content":{"rendered":"

\"\"<\/p>\n

OncoNano COO Brent Sorrells [Composite image; source: OncoNano Medicine\/DI Studio]<\/p>\n

Dallas cancer therapeutic company OncoNano Medicine has named Brent Sorrells as its new chief operating officer.<\/strong><\/p>\n

With more than two decades of experience in product development, strategic operations, and commercial execution across the biotechnology industry, Sorrells will help drive OncoNano\u2019s next phase of growth and operational excellence, the company said.<\/p>\n

\u201cBrent joins OncoNano at a pivotal inflection point as we advance our first polymer drug conjugate from our ON-BOARD micelle platform into IND-enabling studies and continue development of ONM-501, our dual-acting STING agonist,\u201d CEO Kartik Krishnan, M.D., said in a statement. \u201cBrent\u2019s extensive operational and leadership experience will be instrumental as we advance our strategic priorities and continue to execute on key growth milestones.\u201d<\/p>\n

OncoNano\u2019s name\u2014a fusion of oncology and nanotechnology<\/a>\u2014communicates its core mission to develop cancer treatments using nanotechnology. Founded in 2014 and now based at Dallas\u2019s Pegasus Park, the clinical-stage company is pioneering the use of nanotech in the long-standing battle against cancer.<\/p>\n

Sorrells most recently served as VP of product development and strategy at Allakos, Inc., until its acquisition in May 2025. During his time at Allakos, he held various leadership roles in clinical operations. Sorrells previously served in leadership within the clinical team at Fort Worth\u2019s ZS Pharma, which was acquired by AstraZeneca in 2015 for $2.7 billion. He has also worked for and served as board chair at TechFW, the Fort Worth-based nonprofit business incubator for tech startups.<\/p>\n

\u201cOncoNano\u2019s vision to redefine how cancer is treated through targeted delivery of medicines to improve their therapeutic index is truly compelling,\u201d said Sorrells. \u201cThe science, the team, and the opportunity to make a real difference for patients make this an incredibly exciting time to come on board.\u201d<\/p>\n

OncoNano Medicine is a clinical-stage biotechnology company aiming to transform cancer therapeutics with its proprietary nanotechnology platform. OncoNano\u2019s polymeric micelle platform is designed to leverage a universal tumor target, namely pH, to precisely deliver anti-cancer payloads to the tumor microenvironment.<\/p>\n

Don\u2019t miss what\u2019s next. Subscribe\u00a0to\u00a0Dallas\u00a0Innovates.<\/p>\n

Track Dallas-Fort Worth\u2019s business and innovation landscape with our curated news in your inbox Tuesday-Thursday.<\/p>\n

\u00a0<\/p>\n

\tR E A D\u00a0\u00a0 N E X T\t<\/p>\n